isotretinoin and Macular-Degeneration

isotretinoin has been researched along with Macular-Degeneration* in 7 studies

Reviews

1 review(s) available for isotretinoin and Macular-Degeneration

ArticleYear
Lipofuscin and macular degeneration.
    Nutrition reviews, 2003, Volume: 61, Issue:10

    The accumulation of the autofluorescent pigment lipofuscin in the retina that occurs with aging has been explained as a side effect of the visual cycle. It occurs when two molecules of all-trans-retinal condense with one molecule of phosphatidylethanolamine in the discs of the rod outer segments, and is followed by uptake into retinal pigment epithelium (RPE) and conversion to the stable A2E, a pyridinium bisretinoid that is toxic to RPE cells. The accumulation of A2E, the major component of lipofuscin causes RPE cell apoptosis, thereby explaining age-related macular degeneration and macular degeneration characteristic of Stargardt disease. The drug isotretinoin (13-cis-retinoic acid) prevents accumulation of A2E in mice by slowing down the visual cycle and might therefore be used to prevent macular degeneration.

    Topics: Aging; Animals; Humans; Isotretinoin; Lipofuscin; Macular Degeneration; Mice; Pyridinium Compounds; Rats; Retinoids

2003

Trials

1 trial(s) available for isotretinoin and Macular-Degeneration

ArticleYear
One-year results of a pilot study using oral 13-cis retinoic acid as a treatment for subfoveal predominantly occult choroidal neovascularization in patients with age-related macular degeneration.
    Retina (Philadelphia, Pa.), 2006, Volume: 26, Issue:3

    To evaluate the safety and evidence of efficacy for oral 13-cis retinoic acid as a treatment for patients with subfoveal occult choroidal neovascularization (CNV) due to age-related macular degeneration (ARMD).. Patients with active, subfoveal occult CNV with no prior treatment of the subfoveal component were eligible for inclusion. Patients received 40 mg of 13-cis retinoic acid twice daily for 5 months, stopped treatment for 2 months, and then resumed treatment for 5 months. Patients were observed monthly with Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA), clinical examination, fluorescein angiography, and laboratory testing.. Eleven patients, aged 64 to 88 years, were enrolled and followed for 1 year. Initial VA ranged from 55 (20/40) to 5 (20/400) ETDRS letters (median 48 letters). Mild drug-related side effects (dry skin, chapped lips) occurred in all 11 patients. Three patients experienced more severe side effects (muscle aches, mood swings) and did not resume treatment after the drug holiday. Moderate VA loss occurred in 36% at both 6 and 12 months.. Oral 13-cis retinoic acid is too toxic to be useful in patients with ARMD. Oral 13-cis retinoic acid did not improve vision although it may have slowed visual acuity loss in patients with ARMD with occult subfoveal CNV.

    Topics: Administration, Oral; Aged; Aged, 80 and over; Choroidal Neovascularization; Female; Fluorescein Angiography; Follow-Up Studies; Fovea Centralis; Humans; Isotretinoin; Macular Degeneration; Male; Middle Aged; Pilot Projects; Treatment Outcome; Visual Acuity

2006

Other Studies

5 other study(ies) available for isotretinoin and Macular-Degeneration

ArticleYear
Diagnostic and therapeutic challenges.
    Retina (Philadelphia, Pa.), 2008, Volume: 28, Issue:1

    Topics: Adolescent; Dermatologic Agents; Electrooculography; Fluorescein Angiography; Humans; Isotretinoin; Macular Degeneration; Male; Pigment Epithelium of Eye; Scotoma; Visual Acuity

2008
Isotretinoin treatment inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration.
    Novartis Foundation symposium, 2004, Volume: 255

    Recessive Stargardt's macular degeneration is an inherited blinding disease of children caused by mutations in the ABCR gene. The primary pathologic defect in Stargardt's discase is accumulation of toxic lipofuscin pigments such as N-retinylidene-N-retinylethanolamine (A2E) in cells of the retinal pigment epithelium (RPE). This accumulation appears to be responsible for the photoreceptor death and severe visual loss in Stargardt's patients. Here, we tested a novel therapeutic strategy to inhibit lipofuscin accumulation in a mouse model of recessive Stargardt's disease. Isotretinoin (Accutane) has been shown to slow the synthesis of 11-cis-retinaldehyde (11cRAL) and regeneration of rhodopsin by inhibiting 11-cis-retinol dehydrogenase (11cRDH) in the visual cycle. Light activation of rhodopsin results in its release of all-trans-retinaldehyde (atRAL), which constitutes the first reactant in A2E biosynthesis. Accordingly, we tested the effects of isotretinoin on lipofuscin accumulation in abcr-/- knockout mice. Isotretinoin blocked the formation of A2E biochemically and the accumulation of lipofuscin pigments by electron microscopy. We observed no significant visual loss in treated abcr-/- mice by electroretinography. Isotretinoin also blocked the slower, age-dependent accumulation of lipofuscin in wild-type mice. These results corroborate the proposed mechanism of A2E biogenesis. Further, they suggest that treatment with isotretinoin may inhibit lipofuscin accumulation and thus delay the onset of visual loss in Stargardt's patients. Finally, the results suggest that isotretinoin may be an effective treatment for other forms of retinal or macular degeneration associated with lipofuscin accumulation.

    Topics: Animals; Disease Models, Animal; Enzyme Inhibitors; Esters; Isotretinoin; Lipofuscin; Macular Degeneration; Mice; Retinaldehyde; Time Factors

2004
Light exposure stimulates formation of A2E oxiranes in a mouse model of Stargardt's macular degeneration.
    Proceedings of the National Academy of Sciences of the United States of America, 2004, Apr-20, Volume: 101, Issue:16

    Recessive Stargardt's macular degeneration is a blinding disease of children caused by mutations in the ABCA4 (ABCR) gene. Mice with a knockout mutation in abcr accumulate toxic lipofuscin pigments in ocular tissues, similar to affected humans. The major fluorophore of lipofuscin is the bis-retinoid, N-retinylidene-N-retinylethanolamine (A2E). In the current study, we sought to define the effect of increasing light on A2E accumulation. We crossed the abcr(-/-) mutation onto an albino background. The retinoid profiles in albino mice indicated higher retinal illuminance than in pigmented mice exposed to similar ambient light. Unexpectedly, A2E levels were not higher in the albino mice. Also, A2E levels in abcr(-/-) mice reared under cyclic light at 30, 120, or 1,700 lux were similar. Thus, increased retinal illuminance was not correlated with higher A2E. A2E has been shown to undergo light-dependent oxidation to yield a series of A2E epoxides or oxiranes. These oxiranes react with DNA in vitro, suggesting a potential mechanism for A2E cytotoxicity. We analyzed ocular tissues from abcr(-/-) mice for A2E oxiranes by mass spectrometry. Unlike A2E, the oxiranes were more abundant in albino vs. pigmented abcr(-/-) mice, and in abcr(-/-) mice exposed to increasing ambient light. These observations suggest that both the biosynthesis of A2E and its conversion to oxiranes are accelerated by light. Finally, we showed that the formation of A2E oxiranes is strongly suppressed by treating the abcr(-/-) mice with Accutane (isotretinoin), an inhibitor of rhodopsin regeneration.

    Topics: Adaptation, Physiological; Animals; ATP-Binding Cassette Transporters; Chromatography, High Pressure Liquid; Disease Models, Animal; Ethylene Oxide; Isotretinoin; Light; Macular Degeneration; Mass Spectrometry; Mice; Mice, Inbred BALB C

2004
Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration.
    Proceedings of the National Academy of Sciences of the United States of America, 2003, Apr-15, Volume: 100, Issue:8

    Recessive Stargardt's macular degeneration is an inherited blinding disease of children caused by mutations in the ABCR gene. The primary pathologic defect in Stargardt's disease is accumulation of toxic lipofuscin pigments such as N-retinylidene-N-retinylethanolamine (A2E) in cells of the retinal pigment epithelium. This accumulation appears to be responsible for the photoreceptor death and severe visual loss in Stargardt's patients. Here, we tested a therapeutic strategy to inhibit lipofuscin accumulation in a mouse model of recessive Stargardt's disease. Isotretinoin (Accutane) has been shown to slow the synthesis of 11-cis-retinaldehyde and regeneration of rhodopsin by inhibiting 11-cis-retinol dehydrogenase in the visual cycle. Light activation of rhodopsin results in its release of all-trans-retinaldehyde, which constitutes the first reactant in A2E biosynthesis. Accordingly, we tested the effects of isotretinoin on lipofuscin accumulation in abcr(-/-) knockout mice. Isotretinoin blocked the formation of A2E biochemically and the accumulation of lipofuscin pigments by electron microscopy. We observed no significant visual loss in treated abcr(-/-) mice by electroretinography. Isotretinoin also blocked the slower, age-dependent accumulation of lipofuscin in wild-type mice. These results corroborate the proposed mechanism of A2E biogenesis. Further, they suggest that treatment with isotretinoin may inhibit lipofuscin accumulation and thus delay the onset of visual loss in Stargardt's patients. Finally, the results suggest that isotretinoin may be an effective treatment for other forms of retinal or macular degeneration associated with lipofuscin accumulation.

    Topics: Animals; ATP-Binding Cassette Transporters; Dark Adaptation; Disease Models, Animal; Genes, Recessive; Humans; Isotretinoin; Lipofuscin; Macular Degeneration; Mice; Mice, Knockout; Microscopy, Electron; Models, Biological; Pigment Epithelium of Eye; Pyridinium Compounds; Retinal Pigments; Retinoids; Rod Cell Outer Segment

2003
Therapy for macular degeneration: insights from acne.
    Proceedings of the National Academy of Sciences of the United States of America, 2003, Apr-15, Volume: 100, Issue:8

    Topics: Acne Vulgaris; Animals; Humans; Isotretinoin; Macular Degeneration; Mice; Models, Biological; Photobiology; Pigment Epithelium of Eye; Pyridinium Compounds; Retinoids

2003